Lupin Ltd

1. Lupin Ltd Quarter 3 Investor Presentation

2. Corporate Highlights – Q3 10-11 • 19 consecutive quarters of growth in sales and profits • Net sales grew by 17% to Rs. 14,672 million during Q3, FY 2010-11, up from Rs. 12,554 million (Q3 FY 09-10) • Net profits grew by 39% to Rs. 2,240 million during Q3, FY 2010-11, as compared to Rs 1,606 Mn. (Q3 FY 09-10) • Growth across all geographies • US business grew by 15% in USD terms • Japan grew by 12% in JPY terms • S African business grew at 37% in ZAR terms • India Region sales continued to grow at 16% • Capex spend at Rs 107 Crores to meet expected demand. • Revenue Expenditure on R&D increased by 0.5% to Rs. 1178 Mn., amounting to 8% of Net Sales during Q3, FY 2010-11, as against Rs. 939 Mn., 7.5% of Net Sales (Q3, FY 2009-10) • During the quarter the company filed 5 ANDA’s bringing the Cumulative filings as of Q3, FY 2010-11, to 137 filings, of which 47 have been approved by the US FDA • Strategic alliance with Farmanguinhos and Department of Health, Brazil. • Settled litigations with Sunovion over Generic of Lunesta

3. Financial Trend YTD December 2010-11…. Sales +21% EBIDTA +27% PAT +38%

4. Financial Trend Q3 2010-11…. Sales +17% EBIDTA +15% PAT +39% All figures are in Mn

5. Financial Highlights : Q3 10-11

6. Balance Sheet Ratios Rs Mn

7. Business Break up Revenue Mix : Q3 10-11 Geographical Break up FD Sales

8. Corporate Highlights FY 09-10 • 15 consecutive quarters of growth in sales and profits • Growth across all geographies • US business grew by 28% in dollar terms • Japan grew by 10% in JPY terms • S African business grew at 34% in ZAR terms • India Region sales continued growth rate at 18% • Capex spend at Rs 443 Crores to meet expected demand • Year of strong research delivery • 37 ANDAs and 19 DMFs filed in the year • IP settlements – Lotrel (Benazepril/Amlodipine), Namenda (Memantine) • Licensing of Rifaximin ER to Salix for the US • Year of Regulatory compliance • Mandideep facility cleared of Warning Letter in 7.5 months • All plants inspected by FDA

9. Financial Trend 09-10….. Sales +25% EBIDTA +34% PAT +36% CAGR 45% CAGR 49% CAGR29% All figures are in Mn

10. Business Update

11. Advanced Markets – US and Europe USD 000 • Generics – EU • Recorded impressive growth of 72% during the quarter. • Launched Trimetazidine, where Lupin was the first to get approval • Launched Clarithromycin XL in France during the quarter • Cefpodoxime Proxetil tabs France – 72% market share • Ceftiofur – Ranked #1 generic • Branded • Branded portfolio forms 29% of US Turnover • Generics – US • Settled ongoing litigations with Sunovion over Generic of Lunesta. • 5th largest Generic player in the U.S. in terms of prescriptions (IMS Health) • Generics business grew by 49% • No. 1 in 13 out of 29 products marketed • Top 3 in 28 of the 29 products

12. Rs Mn India Region Formulations • Aggressive focus on brand building • Extensive collaboration with thought leading institutions • Continues to be among the fastest growing pharma company in the domestic space @ 16% • Contributed 27% to Lupin’s overall revenues during Q3, FY 2010-11 • Branded business grew by 14% • Current Field Force strength at 4183 • 6 products find a place among the top 300 in the industry • 11 new products launched in the Quarter

13. JPY Mn Japan • Profit enhancement measures to yield greater results in the days to come • Registered Net Sales of Rs. 1727 Mn and contributed 12% to Lupin’s consolidated revenues during the quarter • Identified 4 products for manufacturing shift to Goa plant • Launched 5 new products till date, namely Latanoprost ED Fluvoxamine , Rabeprazole, Omeprazole Inj and Glimeperide • Market leader in Risperidone in terms of units • Significant player in Amlodipine

14. ZAR Mn South Africa • Sixth largest generic company in the S African market • Leading presence in CVS • Several new products under registration • Future growth through improved generics, IP challenges and in-licensing • Growth sustained at over 37% in ZAR terms • Leaders in Amlodipine and Bilocor in unit sales

15. ROW • New brand launches in Philippines • Women’s health, primary care and pediatric segments • Brand acquisition and in-licensing – a common theme across markets • OTC promotion support in mass media • Created thrust in three countries across CIS – Russia, Ukraine and Kazakhstan • Strategic focus on tender / hospital business paying rich dividends in CIS • Increased focus on brand building and entry into retail chains

16. API and Intermediates • Cost, quality and reliability are the cornerstones of our API strategy • Global leadership in chosen therapies • Cephs • Ceph-intermediates • Anti-TB range • Lisinopril • India’s most profitable API entity – ROCE 36% • Achieved global cost, capacity and marketshare leadership in most products • Strategic input into formulations business

17. Research and Development • Talent pool of 700+ scientists • 137 ANDAs, 105 DMFs • Litigation Settlements – Loestrin Fe, Femcon Fe. • Ability to churn out rich pipeline across geographies • Increased focus on F2F and Para IV’s • Strength in drug delivery • Bioadhesive • Laser-drilled • Matrix/coated • Taste-masking • Revamping Drug Discovery • Requisite infrastructure in place • Total expenditure Q3 2010-11 – Rs. 1,178 Mn, 8% of Net sales

18. US Generics Pipeline • 137 products filed, 47 approved • Para IV’s addressing market size of US$ 30 Bn • F2Fs – Desloratadine, Memantine, Duloxetine, Eszopiclone, Ziprasidone, Lanthanum Carbonate, Pregabalin, Lo-Seasonique, Seasonale • Exclusive F2Fs – Fortamet, Glumetza, Cipro DS • Differentiated products • Oral contraceptives • Ophthalmic • Niche products – Niacin XR, Esomeprazole, Tricor, Sevelamer

19. The Way Ahead

20. Lupin’s Core Strength in Generics Managing the Environment Advantage • Local market knowledge • Speed & agility • High quality products • Low cost manufacturing

21. Focal Points Increase Market Share Increase Margins

22. Thank You